Quote | Super Quote
IPO   |   IPO News   |   Listed IPO Information   |   Hot Listed IPO
Stock Code   IPO News IPO Timetable
IPO Detail
06938 瑞博生物－Ｂ
RIBOLIFE-B
Listing Date2026/01/09    Listing Tomorrow
Listing Price57.970
Grey Market Performance
Last updated: 08/01/2026 19:59  Refresh
  • Bright Smart
    up 74.600 +16.630 (+28.687%)
    High
    76.750
     
    Low
    61.100
    Volume
    34,800
    One Lot Profit
    +3,326.00
  • Phillip
    up 74.800 +16.830 (+29.032%)
    High
    77.000
     
    Low
    61.000
    Volume
    1,480,000
    One Lot Profit
    +3,366.00
  • Futu
    up 78.000 +20.030 (+34.552%)
    High
    81.000
     
    Low
    62.950
    Volume
    1,349,000
    One Lot Profit
    +4,006.00
  • Bid
  • Ask
  • 73.400
  • (1) 200
  • 400 (2)
  • 74.850
  • 73.350
  • (1) 400
  • 1.2K (1)
  • 74.900
  • 73.300
  • (0) 0
  • 0 (0)
  • 74.950
  • 73.250
  • (0) 0
  • 0 (0)
  • 75.000
  • 73.200
  • (0) 0
  • 0 (0)
  • 75.050
  • 73.150
  • (0) 0
  • 0 (0)
  • 75.100
  • 73.100
  • (0) 0
  • 0 (0)
  • 75.150
  • 73.050
  • (0) 0
  • 0 (0)
  • 75.200
  • 73.000
  • (1) 400
  • 0 (0)
  • 75.250
  • 72.950
  • (0) 0
  • 0 (0)
  • 75.300
  • Bid
  • Ask
  • 74.750
  • (1) 400
  • 600 (1)
  • 74.800
  •  
  • (1) 6K
  • 0 (0)
  •  
  •  
  • (1) 400
  • 0 (0)
  •  
  •  
  • (2) 1.4K
  • 0 (0)
  •  
  •  
  • (2) 1.4K
  • 2.4K (6)
  •  
 
Hide
COMPANY PROFILE

Suzhou Ribo Life Science Co. was founded in 2007, it is a biopharmaceutical company engaged in oligonucleotide research and development, with a focus on siRNA therapeutics.

--

The Group has one Core Product, RBD4059 (FXI-targeting siRNA), targeting thrombotic diseases, among a pipeline of seven in-house discovered drug assets in clinical trials for seven indications across cardiovascular, metabolic, renal and liver diseases, including four in phase 2 clinical trials.

--

Leveraging the Group’s RiboGalSTAR platform equipped with proprietary and clinically validated GalNAc delivery technology, it has consistently advanced siRNA programs in-house from discovery through clinical development.

--

Besides the Group’s Core Product RBD4059, it is advancing other clinical-stage products, including RBD5044 and RBD1016. Beyond the Group’s clinical pipeline, it maintain over 20 preclinical programs that it aim to advance into clinical development. The Group’s revenue was primarily from its licensing and collaboration arrangements.

BASIC INFORMATION
MarketHong Kong (Main Board)
Business NatureHealth Care
Major Business AreaChina
Board Lot200
GLOBAL OFFERING
No. of Offer Shares27.49M H shares
No. of International Offer Shares24.74M H shares
No. of HK Offer Shares2.75M H shares
Offer Price$57.97
Stock Code6938
Sponsor(s)China International Capital Corporation Hong Kong Securities Limited, Citigroup Global Markets Asia Limited
Underwriter(s)China International Capital Corporation Hong Kong Securities Limited, Citigroup Global Markets Asia Limited, ICBC International Securities Limited, BOCI Asia Limited, Macquarie Capital Limited, ABCI Securities Company Limited, SDIC Securities (Hong Kong) Limited, Futu Securities International (Hong Kong) Limited
TIME TABLE
Application PeriodDec 31 (Wed) - noon, Jan 06 (Tue)
Price Determination DateJan 06 (Tue)
Result Announcement DateOn or before Jan 08 (Thu)
Result Announcement DateOn or before Jan 08 (Thu)
Result Announcement DateOn or before Jan 09 (Fri)
Dealings in Shares commence onJan 09, 2026. (Fri)
Reallocation of Shares Offered
Sales Statistics (HKD)
Offer Price$57.97
Capitalization9.37B
NAV / share ($)$8.5 (Unaudited pro forma adj NAV / share)
Use Of Proceeds
Assuming the offer price being at HKD 57.97, the net proceeds raised would be HKD 1.47B, of which
37.4% : Research and development of Core Product RBD4059
19.6% : Research and development of RBD5044
15.9% : Research and development of RBD1016
10.1% : Fund the research and development of our IND-enabling pipeline assets
8.9% : Advance preclinical assets which have not yet entered the IND-enabling stage and enhance technology platforms
8.1% : Working capital
IPO NEWS
08/01/2026 18:35
{New Stock}RIBOLIFE-B(06938) ends up 29.03% on grey market
08/01/2026 16:20
{New Stock}RIBOLIFE-B up 28.52% at HK$74.5 on grey market
Related Document
Prospectus Prospectus  Chinese VersionProspectus  English Version
Remark： The above information is referenced from the prospectus.
  All data is calculated from the non- exercise rights(if applicable).
IPO Calculator
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --
Offer Price︰--
Currency :
Listing Price :
Board Lot :
Admission Fee*
 :
Subscribing Lot :
Subscribing Fee :
Subscribing Amount :
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2026 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.